01307nas a2200265   4500000000100000008004100001260001300042653002400055653002000079653003000099653001100129653001600140653001100156653001200167653000900179653002000188100001400208700001500222700001500237245009500252300001000347490000700357520066300364022001401027       1993                            d  c1993 Jan10aAntigens, Bacterial10aDrug Monitoring10aDrug Therapy, Combination10aFemale10aGlycolipids10aHumans10aleprosy10aMale10aSerologic Tests1 aPrakash K1 aSehgal V N1 aAggarwal R00aEvaluation of phenolic glycolipid-I (PGL-I) antibody as a multidrug therapy (MDT) monitor.  a16-200 v203 a<p>Since phenolic glycolipid-I (PGL-I) is an unequivocal marker for Mycobacterium leprae, this antigen has been a good candidate for the serodiagnosis and monitoring of the effectiveness of leprosy chemotherapy. The present study, a continuation of an earlier report, was undertaken to estimate PGL-I antibody titers in 40 leprosy patients 3 and 6 months after starting MDT. All the leprosy groups showed significant declines in anti PGL-I reactivity after 6 months. There was a good correlation between bacteriological indices (BI) and anti PGL-I antibody levels. Thus, PGL-I based serology may be useful in monitoring the response to multidrug therapy.</p>  a0385-2407